Table 4.
Clinical parameters associated with concurrent radiochemotherapy response
| Variable | No. of patients | Responders n (%) | Non responders n (%) | p value | ||
|---|---|---|---|---|---|---|
| CR+PR | ST+PD | |||||
| FIGO stage | ||||||
| IIB | 67 | 15 (22.4) | 52 (77.6) | <0.01 | ||
| IIIA | 87 | 9 (10.4) | 78 (89.7) | |||
| IIIB | 53 | 1 (1.2) | 52 (98.1) | |||
| Tumor size (baseline) | ||||||
| ≤ 4 cm | 107 | 18 (16.8) | 89 (83.2) | 0.03 | ||
| > 4 cm | 100 | 7 (7) | 93 (93) | |||
| Age | ||||||
| ≤ 44 years | 54 | 3 (5.6) | 51 (94.4) | 0.09 | ||
| > 44 years | 153 | 22 (14.4) | 131 (85.6) | |||
| Hb level (initial) | ||||||
| ≤ 12 mg/dl | 39 | 3 (7.7) | 36 (92.3) | 0.51 | ||
| > 12 mg/dl | 168 | 22 (13.1) | 146 (86.9) | |||
| Neoadjuvant chemotherapy regimen | ||||||
| Paclitaxel + Carboplatin | 177 | 24 (13.6) | 153 (86.4) | 0.20 | ||
| Topotecan + Cisplatin | 30 | 1 (3.3) | 29 (96.7) | |||
| NACT No. of cycles | ||||||
| 1-2 cycles | 81 | 8 (9.9) | 73 (90.1) | 0.44 | ||
| 3-4 cycles | 126 | 17 (13.5) | 109 (86.5) | |||
| Histological type | ||||||
| Squamous cell carcinoma | 182 | 22 (12.1) | 160 (87.9) | 0.75 | ||
| Adenocarcinoma | 25 | 3 (12) | 22 (88) | |||
| Cervical boost | ||||||
| BT | 89 | 19 (21.3) | 70 (78.7) | 0.44 | ||
| Arch technique | 33 | 5 (15.2) | 28 (84.8) | |||